Abstract 141P
Background
Transurethral resection of bladder tumor (TURBT) combined with concurrent chemoradiotherapy is the standard treatment for bladder preservation in MIBC. TURBT alone and partial cystectomy are only suitable for selected patients with solitary tumors, T2, and tumors in the bladder diverticulum. One of the major concerns is the possibility of residual tumor and the increasing risk of metastasis after surgery. Systemic treatment after radical TURBT or partial cystectomy may prevent recurrence and metastasis. This study aims to explore the efficacy and safety of T combined with GC after radical TURBT or partial cystectomy as bladder preservation therapy in patients with PD-L1 positive MIBC.
Methods
This study is a prospective phase II clinical trial. Eligible patients must have clinical stage T2-T3N0M0, histologically confirmed urothelial carcinoma, PD-L1 positive, no previous systemic treatment, and no residual tumor after radical TURBT or partial cystectomy. Patients received T combined with GC (G 1000mg/m2, d1, d8; C 70mg/m2, d1, IV, q3w, for a total of 6 cycles. T 200mg, d8, IV, q3w, for a total of 8 cycles). The primary endpoint was 1-year bladder intact disease-free survival rate. Secondary endpoints included 2-year bladder intact disease-free survival rate, metastasis-free survival, time to salvage cystectomy, overall survival, and safety.
Results
From August 2022 to June 2024, a total of 10 patients were enrolled in the study. Median age was 70 years (65-75). 9 patients were T2 and 1 patient was T3. 8 patients were evaluable for efficacy. 5 patients underwent TURBT and 3 patients underwent partial cystectomy. The median follow-up time was 10.5 months. None of the 8 patients had tumor recurrence or metastasis. 1-year bladder intact disease-free survival rate was 100%. Grade 3 or higher adverse events occurred in 37.5% of patients. No new safety signals were observed.
Conclusions
The study demonstrated that combination of T and GC after complete resection of tumor seemed promising as bladder preservation strategy in selected patients. Further recruitment is ongoing.
Clinical trial identification
NCT05401279.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract